Neuroskin Psoriasis Relief DRTV test results announced by avVaa World Health Care

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced the results of its first DRTV test week.

avVaa World Health Care Products, Inc. announced a successful first test for the Neuroskin(R) Psoriasis Relief DRTV media campaign. A total of 32 DRTV commercials were shown between August 24 and September 1, 2009, using both hard and soft sell formats. Consumer response was immediate and very high, with over 90 phone calls and 1200 website hits.

"Our call center conversion rate was strong," stated Lorie Campbell-Farley, President and COO. "Half of our callers placed an order, and 57% of those who ordered upgraded their purchase to at least 3 bottles." Call center representatives reported that approximately 5% of callers did not have a credit card, so did not purchase. In response, avVaa added check by phone services in early September.

The incredible website response made it clear that a majority of consumers prefer to purchase online. There were 1200 views of www.MyNeuroskin.com, with an average of 4 minutes being spent on the site. This indicates that a majority of viewers moved ahead to the checkout page, which is done by typing in shipping information and clicking 'Rush My Order Now. However, the website was unable to process credit card orders at the time.

"Unfortunately we were unable to capitalize on our web ordering until the end of the test week," said Mrs. Campbell-Farley. "There were significant delays from the vendor in receiving our credit card processing. We had been assured we would be up and running by August 21, but did not receive our final setup until September 1." Web ordering became available late in the day on September 1st, and orders began coming in immediately.

As a result of the test week, avVaa is looking at alternative media buying options. "Our audience reach was not satisfactory," commented Mrs. Campbell-Farley. "It is a testimonial to the strength of our Neuroskin product that it received such a strong response. We are looking at options for getting better time slots and higher saturation for the money we spend.

"We are very confident in the marketability of Neuroskin(R) Psoriasis Relief. The strong consumer response definitely justifies a second test, which we anticipate launching within the next two weeks."

Should this second test be as successful as the first one, then avVaa will at that time be confident enough to start their national media campaign shortly thereafter. "It is always best to resolve all issues in test phases, and by doing so, when all the kinks have been resolved, we will be confident that both a national infomercial campaign and internet campaign, which was announced on September 14th, 09 will jointly produce exceptional results for the Company and for all our shareholders. The next couple of months will be monumental for avVaa, and we are excited to roll out our psoriasis product to the world", concluded Mrs. Campbell-Farley.